Compare YieldMax Universe Fund of Option Income ETFs (YMAX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax Universe Fund of Option Income ETFs vs Zimmer Biomet Holdings Inc — how do they compare? YieldMax Universe Fund of Option Income ETFs trades at $7.53, while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $18.05B). The key difference: Zimmer Biomet Holdings Inc pays a 1.01% dividend while YieldMax Universe Fund of Option Income ETFs pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| YMAX | ZBH | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $13.14 | $104.26 |
52-Week Low | $7.27 | $79.58 |
Market Cap | — | $18.05B |
Enterprise Value | — | $25.11B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
YMAX trades at $7.70, up 0.13% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF maintains a high distribution yield, with weekly dividends averaging around $0.06-$0.07 recently. However, the share price has declined year-to-date, indicating potential NAV erosion despite income payouts.
The outlook is mixed: high yields attract income investors, but structural costs and NAV decay pose sustainability risks. Key risks include distribution policy strain and fee stacking. Analyst sentiment is cautious, with some recommending holds due to principal erosion concerns amid volatile market conditions.
ZBH trades at $94.22, down 3.93% on the day, with a bearish technical signal but oversold RSI readings. Recent earnings beats and raised 2026 guidance support fundamentals, with revenue growth and strong gross margins. Leadership promotions aim to accelerate commercial transformation, while cash flow trends show operational strength.
The stock offers upside to the $104.88 consensus target, but faces headwinds from debt levels and competitive pressures. Near-term support at $92 is critical; a hold rating aligns with mixed analyst views. Earnings execution and procedure demand growth are key catalysts for valuation expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
